50. Dermatomyositis Clinical trials / Disease details

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03192657 (ClinicalTrials.gov)	July 2017	15/6/2017	Basiliximab Treating Interstitial Pneumonia of CADM	Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients	Lung; Disease, Interstitial, With Fibrosis;Dermatomyositis	Drug: Basiliximab;Drug: Calcineurin Inhibitors;Drug: Steroids	RenJi Hospital	NULL	Not yet recruiting	18 Years	65 Years	All	100	Phase 2	China
2	EUCTR2005-003129-23-GB (EUCTR)	18/04/2006	24/02/2006	To prevent and treat osteoporosis in children with rhuematic diseases taking steroids	Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases - POPS	Children and adolescents with Juvenile Idiopathic arthritis (JIA), Juvenile dermatomyositis (JDMS) Juvenile systemic lupus erythematosis (JSLE) Vasculitis;Therapeutic area: Body processes [G] - Immune system processes [G12]	Product Name: Risedronate Sodium Product Code: 35mg Other descriptive name: RISEDRONATE SODIUM Product Name: Risedronate Sodium Product Code: 5mg Other descriptive name: RISEDRONATE SODIUM Trade Name: One-Alpha drops Product Name: One Alpha Drops Product Code: alfacalcidol 2 micrograms/ml INN or Proposed INN: ALFACALCIDOL Other descriptive name: drops	Belfast Health and Social Care Trust, Musgrave Park Hospital	NULL	Not Recruiting			Female: yes Male: yes	216	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom